Mylan EPS - Earnings per Share 2006-2018 | MYL

Mylan annual and quarterly earnings per share history from 2006 to 2018. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Mylan EPS for the quarter ending December 31, 2018 was $0.10, a 78.72% decline year-over-year.
  • Mylan EPS for the twelve months ending December 31, 2018 was $0.68, a 47.69% decline year-over-year.
  • Mylan 2018 annual EPS was $0.68, a 47.69% decline from 2017.
  • Mylan 2017 annual EPS was $1.3, a 41.3% increase from 2016.
  • Mylan 2016 annual EPS was $0.92, a 45.88% decline from 2015.
Mylan Annual EPS
2018 $0.68
2017 $1.30
2016 $0.92
2015 $1.70
2014 $2.34
2013 $1.58
2012 $1.52
2011 $1.22
2010 $0.68
2009 $0.30
2008 $-1.10
2007 $-4.53
2007 $0.99
2006 $0.79
2005 $0.74
Mylan Quarterly EPS
Q4 2018 $0.10
Q3 2018 $0.34
Q2 2018 $0.07
Q1 2018 $0.17
Q4 2017 $0.47
Q3 2017 $0.16
Q2 2017 $0.55
Q1 2017 $0.12
Q4 2016 $0.79
Q3 2016 $-0.23
Q2 2016 $0.33
Q1 2016 $0.03
Q4 2015 $0.42
Q3 2015 $0.83
Q2 2015 $0.32
Q1 2015 $0.13
Q4 2014 $0.47
Q3 2014 $1.26
Q2 2014 $0.32
Q1 2014 $0.29
Q4 2013 $0.45
Q3 2013 $0.40
Q2 2013 $0.46
Q1 2013 $0.27
Q4 2012 $0.38
Q3 2012 $0.51
Q2 2012 $0.33
Q1 2012 $0.30
Q4 2011 $0.30
Q3 2011 $0.36
Q2 2011 $0.33
Q1 2011 $0.23
Q4 2010 $-0.01
Q3 2010 $0.33
Q2 2010 $0.16
Q1 2010 $0.20
Q4 2009 $0.01
Q3 2009 $-0.13
Q2 2009 $0.19
Q1 2009 $0.23
Q4 2008 $-0.05
Q3 2008 $0.47
Q2 2008 $-0.05
Q1 2008 $-1.47
Q4 2007 $-5.14
Q3 2007 $0.60
Q2 2007 $0.32
Q1 2007 $-0.31
Q4 2006 $0.63
Q3 2006 $0.36
Q2 2006 $0.35
Q1 2006 $0.00
Q4 2005 $0.22
Q3 2005 $0.16
Q2 2005 $0.16
Q1 2005 $0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $14.766B $11.434B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $51.256B 9.23
Teva Pharmaceutical Industries (TEVA) Israel $17.195B 5.93
Bausch Health Cos (BHC) Canada $9.196B 6.54
Dr Reddy's Laboratories (RDY) India $6.567B 26.19
Supernus Pharmaceuticals (SUPN) United States $1.989B 18.46
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.936B 3.15
Homology Medicines (FIXX) United States $1.018B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.964B 89.61
CymaBay Therapeutics (CBAY) United States $0.791B 0.00
Voyager Therapeutics (VYGR) United States $0.600B 0.00
Assembly Biosciences (ASMB) United States $0.508B 0.00
Akorn (AKRX) United States $0.451B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.392B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.219B 0.00
Sol-Gel Technologies (SLGL) Israel $0.129B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.117B 0.00
Acasti Pharma (ACST) Canada $0.084B 0.00
Teligent (TLGT) United States $0.069B 0.00
Agile Therapeutics (AGRX) United States $0.069B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.064B 0.00
Evoke Pharma (EVOK) United States $0.026B 0.00
Aevi Genomic Medicine (GNMX) United States $0.015B 0.00
China Pharma Holdings (CPHI) China $0.014B 0.00